“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Carmat
Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.
Carmat — 4 videos in collection
Stéphane Piat, CEO of Carmat, discusses the limitations of human heart transplant availability that build the commercial case for the development of its biocompatible artificial heart implant. He also outlines the characteristics that differentiate the Carmat heart from the SynCardia artificial heart and from ventricular assistance devices, which can potentially lead to better tolerability, less thrombosis risk and improved patient outcomes. He then discusses the next steps needed to advance the Carmat heart project and summarises the company’s financial position and requirements.
Get access to the very latest content matched to your personal investment style.
